The Food and Drug Administration on Friday authorized a second coronavirus vaccine. For Emergency Use Authority (EUA) ModernaOf (NASDAQ: mRNA) mRNA-1273 comes one day after the agency’s advisory committee unanimously recommended the vaccine and a week later Pfizer (NYSE: PFE) And BioNTech (NASDAQ: BNTX) EUA received for their coronavirus vaccine, BNT162b2.
There are plans to deliver around 20 million doses of the vaccine by the end of the modern month.
European Union drug manufacturers allow their vaccines to be sold in the US as long as the pandemic emergency continues. Both Pfizer and Moderna have stated that they have plans to apply for full approval next year, as they have additional safety data that the FDA requires full approval.
Modern’s vaccine has some advantages over Pfizer and BioNotech’s vaccine, including easy storage requirements. In their respective clinical trials, mRNA-1273 also appeared to provide better protection from severe COVID-19. Of the 196 COVID-19 cases in the clinical trial, none of the participants who received mRNA-1273 developed severe COVID-19, whereas 30 cases in the placebo group were classified as severe.
But Pfizer and BioNTech have some advantages in other areas of BNT162b2. The vaccine is authorized for people 16 years and older, while Modern’s mRNA-1273 is under 18 years of age. The side effect profile, particularly after the second dose, also appears to be milky for Bnt162b2 compared to mRNA-1273.
Of course, in the short term, there will not be much competition between the two vaccines as neither group will be able to manufacture enough vaccines to meet future demand.